Literature DB >> 21215310

Disruption of the mitochondrial thioredoxin system as a cell death mechanism of cationic triphenylmethanes.

Xu Zhang1, Yujuan Zheng, Levi E Fried, Yatao Du, Sergio J Montano, Allie Sohn, Benjamin Lefkove, Lars Holmgren, Jack L Arbiser, Arne Holmgren, Jun Lu.   

Abstract

Alterations in mitochondrial structure and function are a hallmark of cancer cells compared to normal cells and thus targeting mitochondria has emerged as an novel approach to cancer therapy. The mitochondrial thioredoxin 2 (Trx2) system is critical for cell viability, but its role in cancer biology is not well understood. Recently some cationic triphenylmethanes such as brilliant green (BG) and gentian violet were shown to have antitumor and antiangiogenic activity with unknown mechanisms. Here we demonstrate that BG killed cells at nanomolar concentrations and targeted mitochondrial Trx2, which was oxidized and degraded. HeLa cells were more sensitive to BG than fibroblasts. In HeLa cells, Trx2 down-regulation by siRNA resulted in increased sensitivity to BG, whereas for fibroblasts, the same treatments had no effect. BG was observed to accumulate in mitochondria and cause a rapid and dramatic decrease in mitochondrial Trx2 protein. With a redox Western blot method, we found that treatment with BG caused oxidation of both Trx1 and Trx2, followed by release of cytochrome c and apoptosis-inducing factor from the mitochondria into the cytosol. Moreover, this treatment resulted in an elevation of the mRNA level of Lon protease, a protein quality control enzyme in the mitochondrial matrix, suggesting that the oxidized Trx2 may be degraded by Lon protease.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21215310      PMCID: PMC3047390          DOI: 10.1016/j.freeradbiomed.2010.12.036

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  54 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells.

Authors:  Pelle Håkansson; Anders Hofer; Lars Thelander
Journal:  J Biol Chem       Date:  2006-01-24       Impact factor: 5.157

Review 3.  Targeting lipophilic cations to mitochondria.

Authors:  Michael P Murphy
Journal:  Biochim Biophys Acta       Date:  2008-04-08

4.  The redox state of SECIS binding protein 2 controls its localization and selenocysteine incorporation function.

Authors:  Laura V Papp; Jun Lu; Frank Striebel; Derek Kennedy; Arne Holmgren; Kum Kum Khanna
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

5.  Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice.

Authors:  Sulochana S Bhandarkar; Marisa Jaconi; Levi E Fried; Michael Y Bonner; Benjamin Lefkove; Baskaran Govindarajan; Betsy N Perry; Ravi Parhar; Jamie Mackelfresh; Allie Sohn; Michael Stouffs; Ulla Knaus; George Yancopoulos; Yvonne Reiss; Andrew V Benest; Hellmut G Augustin; Jack L Arbiser
Journal:  J Clin Invest       Date:  2009-07-13       Impact factor: 14.808

Review 6.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Authors:  Georg T Wondrak
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

7.  Rat liver thioredoxin and thioredoxin reductase: purification and characterization.

Authors:  M Luthman; A Holmgren
Journal:  Biochemistry       Date:  1982-12-21       Impact factor: 3.162

8.  Neutral red uptake assay for the estimation of cell viability/cytotoxicity.

Authors:  Guillermo Repetto; Ana del Peso; Jorge L Zurita
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

Review 9.  Toxicological effects of malachite green.

Authors:  Shivaji Srivastava; Ranjana Sinha; D Roy
Journal:  Aquat Toxicol       Date:  2004-02-25       Impact factor: 4.964

10.  Ribonucleotide reduction is a cytosolic process in mammalian cells independently of DNA damage.

Authors:  Giovanna Pontarin; Artur Fijolek; Paola Pizzo; Paola Ferraro; Chiara Rampazzo; Tullio Pozzan; Lars Thelander; Peter A Reichard; Vera Bianchi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-07       Impact factor: 11.205

View more
  21 in total

1.  Oxidation of the yeast mitochondrial thioredoxin promotes cell death.

Authors:  Darren Greetham; Paraskevi Kritsiligkou; Rachel H Watkins; Zorana Carter; Jill Parkin; Chris M Grant
Journal:  Antioxid Redox Signal       Date:  2012-08-27       Impact factor: 8.401

2.  Enzyme-activated intracellular drug delivery with tubule clay nanoformulation.

Authors:  Maria R Dzamukova; Ekaterina A Naumenko; Yuri M Lvov; Rawil F Fakhrullin
Journal:  Sci Rep       Date:  2015-05-15       Impact factor: 4.379

Review 3.  Gentian violet: a 19th century drug re-emerges in the 21st century.

Authors:  Alexander M Maley; Jack L Arbiser
Journal:  Exp Dermatol       Date:  2013-12       Impact factor: 3.960

4.  Promoting intolerance: learning from warts.

Authors:  S Rao; J L Arbiser
Journal:  Br J Dermatol       Date:  2017-09       Impact factor: 9.302

Review 5.  The role of the thioredoxin/thioredoxin reductase system in the metabolic syndrome: towards a possible prognostic marker?

Authors:  Alexey A Tinkov; Geir Bjørklund; Anatoly V Skalny; Arne Holmgren; Margarita G Skalnaya; Salvatore Chirumbolo; Jan Aaseth
Journal:  Cell Mol Life Sci       Date:  2018-01-11       Impact factor: 9.261

6.  Mitochondrial-targeted nitroxides disrupt mitochondrial architecture and inhibit expression of peroxiredoxin 3 and FOXM1 in malignant mesothelioma cells.

Authors:  Brian Cunniff; Kira Benson; Jason Stumpff; Kheng Newick; Paul Held; Douglas Taatjes; Joy Joseph; Balaraman Kalyanaraman; Nicholas H Heintz
Journal:  J Cell Physiol       Date:  2013-04       Impact factor: 6.384

Review 7.  Targeting cancer cell mitochondria as a therapeutic approach.

Authors:  Shijun Wen; Daqian Zhu; Peng Huang
Journal:  Future Med Chem       Date:  2013-01       Impact factor: 3.808

8.  Potential suppressive effects of gentian violet on human breast cancer MDA-MB-231 cells in vitro: Comparison with gemcitabine.

Authors:  Masayoshi Yamaguchi; Tomiyasu Murata
Journal:  Oncol Lett       Date:  2016-06-23       Impact factor: 2.967

9.  In vivo Gram staining of tinea versicolor.

Authors:  Allyson Spence-Shishido; Christopher Carr; Michael Y Bonner; Jack L Arbiser
Journal:  JAMA Dermatol       Date:  2013-08       Impact factor: 10.282

10.  Suppression of NF-κB activation by gentian violet promotes osteoblastogenesis and suppresses osteoclastogenesis.

Authors:  M Yamaguchi; T Vikulina; J L Arbiser; M N Weitzmann
Journal:  Curr Mol Med       Date:  2014       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.